Skip to main content
logo
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
4.550
-0.510 (-10.08%)
Nov 5, 2026, 4:00 PM EST - Market closed

Entrada Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3.9825.42210.78129.01--
Revenue Growth
-93.53%-87.94%63.38%---
Cost of Revenue
140.57140.57125.3199.8866.6135.93
Gross Profit
-136.59-115.1585.4829.13-66.61-35.93
Selling, General & Admin
40.1940.8538.4732.2930.6415.2
Research & Development
-7.52-----
Operating Expenses
32.6740.8538.4732.2930.6415.2
Operating Income
-169.26-15647.01-3.16-97.25-51.13
Interest & Investment Income
9.9715.0719.4715.222.630.04
EBT Excluding Unusual Items
-159.29-140.9366.4912.06-94.62-51.08
Merger & Restructuring Charges
-1.9-1.9----
Gain (Loss) on Sale of Assets
------0.07
Pretax Income
-161.19-142.8366.4912.06-94.62-51.16
Income Tax Expense
0.190.920.8618.74--
Net Income
-161.39-143.7565.63-6.69-94.62-51.16
Net Income to Common
-161.39-143.7565.63-6.69-94.62-51.16
Net Income Growth
------
Shares Outstanding (Basic)
42413733316
Shares Outstanding (Diluted)
42413933316
Shares Change
2.00%6.07%18.01%5.62%399.27%467.09%
EPS (Basic)
-3.84-3.471.76-0.20-3.02-8.16
EPS (Diluted)
-3.84-3.471.68-0.20-3.02-8.16
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-136.33-129.55-44.72134.19-96.67-55.44
Free Cash Flow Per Share
-3.25-3.13-1.154.06-3.09-8.85
Gross Margin
--40.55%22.58%--
Operating Margin
-4256.05%-613.66%22.30%-2.45%--
Profit Margin
-4057.98%-565.48%31.14%-5.18%--
Free Cash Flow Margin
-3428.06%-509.63%-21.21%104.01%--
EBITDA
-166.06-151.950.78-0.32-95.35-50.01
EBITDA Margin
--24.09%-0.25%--
D&A For EBITDA
3.24.13.772.841.91.12
EBIT
-169.26-15647.01-3.16-97.25-51.13
EBIT Margin
--22.30%-2.45%--
Effective Tax Rate
--1.29%155.45%--
SEC Filings: 10-K · 10-Q